N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators

A method for treating a Wnt-mediated disorder in a subject suffering therefrom, comprising administering to the subject a compound of Formula (6),

• or a pharmaceutically acceptable salt thereof;
• wherein:
• X1, X2, X3 and X4 is selected from N and CR7;
• one of X5, X6, X7 and X8 is N and the others are CH;
• X9 is selected from N and CH;
• Z is selected from phenyl, pyrazinyl, pyridinyl, pyridazinyl and piperazinyl;
• wherein each phenyl, pyrazinyl, pyridinyl, pyridazinyl or piperazinyl of Z is optionally substituted with an R6 group;
• R1, R2 and R3 are hydrogen;
• m is 1;
• R4 is selected from hydrogen, halo, difluoromethyl, trifluoromethyl and methyl;
• R6 is selected from hydrogen, halo and —C(O)R10;
• wherein R10 is methyl;
• and
• R7 is selected from hydrogen, halo, cyano, methyl and trifluoromethyl;
• and optionally in combination with a chemotherapeutic agent;
• wherein said Wnt-mediated disorder is fibrosis, colorectal cancer, colorectal carcinoma, breast cancer, head and neck squamous cell carcinoma, esophageal cancer, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, brain tumor, Wilm's tumor, basal cell carcinoma, melanoma, or head and neck cancer, cervical cancer, prostate cancer or ovarian cancer.